MarketPulse

Executive Order

2 articles
BenzingaBenzinga··Evette Mitkov

Enveric Surges 106% on Trump's Psychedelics Push, but Downtrend Lingers

$ENVB surges 106% after Trump orders federal acceleration of psychedelic treatment approvals and commits $50M to ibogaine research, though stock remains deeply depressed technically.
ENVBbiotechregulatory approval
The Motley FoolThe Motley Fool··Howard Smith

Compass Pathways Surges 40% on White House Push for Psychedelic Drug Approvals

Compass Pathways stock surges 40% following White House Executive Order accelerating FDA approval of its COMP360 psychedelic therapy for treatment-resistant depression.
CMPSFDA approvaltreatment-resistant depression